Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma

Exclusion Criteria

• •Prior treatment with Docetaxel or Avastin
• •Concurrent immunotherapy or hormonal therapy for the specific purpose of treatment for the ovarian cancer. Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to enrollment in order for the patient to be eligible to participate in this trial. Continuation of hormonal replacement therapy is allowed.
• •Peripheral neuropathy \>/= grade 2
• •History of a severe hypersensitivity reaction to Docetaxel, Avastin, or to other drugs formulated with polysorbate (Tween) 80.
• •Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study of Avastin
• •Blood pressure of \>150/100 mmHg Unstable angina
• •New York Heart Association (NYHA) Grade II or greater congestive heart failure
• •History of myocardial infarction within 6 months prior to Day 1
• •History of stroke within 6 months prior to Day 1
• •Clinically significant peripheral vascular disease
• •Evidence of bleeding diathesis or coagulopathy
• •Presence of central nervous system or brain metastases
• •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
• •Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0
• •Pregnant (positive pregnancy test) or lactating
• •Urine protein: creatinine ratio \>/= 1.0 at screening
• •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
• •Serious, non-healing wound, active ulcer, or untreated bone fracture
• •Evidence of malignancy in the last 5 years, other than nonmelanoma cutaneous carcinomas
• •History of hemoptysis (bright red blood of 1/2 teaspoon or more) within last 3 months
• •Patients believed to possibly be at higher than average risk of perforation will be excluded from study. This includes symptoms or findings of partial or complete bowel obstruction, history of fistula, patients requiring parenteral nutrition and hydration, and those with history of prior perforation due to tumor or perforation within last 6 months from other causes.
• •Inability to comply with study and/or follow-up procedures.
• •Patients who are not on a stable dose of anticoagulation therapy. Patients who are on a stable anticoagulation regimen, including coumadin or low molecular-weight heparin, will not be excluded.